What is Chemours Co's earnings per share (EPS)?

Chemours Co (CC) reported diluted earnings per share of $-2.57 for fiscal year 2025. This represents a -658.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Chemours Co Financials

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Chemours Co (CC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 19/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth

Chemours Co's revenue grew a modest 0.4% year-over-year to $5.8B. This slow but positive growth earns a score of 34/100.

Leverage

Chemours Co has elevated debt relative to equity (D/E of 16.40), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Chemours Co's current ratio of 1.78 indicates adequate short-term liquidity, earning a score of 31/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Chemours Co generated $264.0M in operating cash flow, capex of $213.0M consumed most of it, leaving $51.0M in free cash flow. This results in a low score of 27/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Chemours Co generates a -154.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 12.1% the prior year.

Piotroski F-Score Neutral

4/9

Chemours Co passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.68x

For every $1 of reported earnings, Chemours Co generates $-0.68 in operating cash flow ($264.0M OCF vs -$386.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.8B

YoY+0.4%

5Y CAGR+3.2%

10Y CAGR+0.2%

Chemours Co generated $5.8B in revenue in fiscal year 2025. This represents an increase of 0.4% from the prior year.

EBITDA

N/A

Net Income

-$386.0M

YoY-659.4%

Chemours Co reported -$386.0M in net income in fiscal year 2025. This represents a decrease of 659.4% from the prior year.

EPS (Diluted)

$-2.57

YoY-658.7%

Chemours Co earned $-2.57 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 658.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$51.0M

YoY+105.1%

5Y CAGR-37.6%

Chemours Co generated $51.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 105.1% from the prior year.

Cash & Debt

$670.0M

YoY-6.0%

5Y CAGR-9.5%

10Y CAGR+6.2%

Chemours Co held $670.0M in cash against $4.1B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.51

YoY-48.8%

5Y CAGR-12.5%

10Y CAGR-1.2%

Chemours Co paid $0.51 per share in dividends in fiscal year 2025. This represents a decrease of 48.8% from the prior year.

Shares Outstanding

150M

YoY+0.3%

5Y CAGR-1.9%

10Y CAGR-1.9%

Chemours Co had 150M shares outstanding in fiscal year 2025. This represents an increase of 0.3% from the prior year.

Margins & Returns

Gross Margin

15.5%

YoY-4.2pp

5Y CAGR-5.9pp

10Y CAGR-1.2pp

Chemours Co's gross margin was 15.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.2 percentage points from the prior year.

Operating Margin

N/A

Net Margin

-6.7%

YoY-7.8pp

5Y CAGR-11.1pp

10Y CAGR-5.1pp

Chemours Co's net profit margin was -6.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.8 percentage points from the prior year.

Return on Equity

-154.4%

YoY-166.5pp

5Y CAGR-181.3pp

10Y CAGR-83.0pp

Chemours Co's ROE was -154.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 166.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$108.0M

YoY-0.9%

5Y CAGR+3.0%

10Y CAGR+1.1%

Chemours Co invested $108.0M in research and development in fiscal year 2025. This represents a decrease of 0.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$213.0M

YoY-40.8%

5Y CAGR-4.4%

10Y CAGR-8.5%

Chemours Co invested $213.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 40.8% from the prior year.

CC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.8B+0.4%	$5.8B-4.9%	$6.1B-11.0%	$6.8B+7.7%	$6.3B+27.7%	$5.0B
Cost of Revenue	$4.9B+5.7%	$4.6B-2.8%	$4.8B-8.4%	$5.2B+5.1%	$5.0B+27.2%	$3.9B
Gross Profit	$902.0M-21.0%	$1.1B-12.3%	$1.3B-19.4%	$1.6B+17.0%	$1.4B+29.4%	$1.1B
R&D Expenses	$108.0M-0.9%	$109.0M+0.9%	$108.0M-8.5%	$118.0M+10.3%	$107.0M+15.1%	$93.0M
SG&A Expenses	$799.0M+33.6%	$598.0M-53.5%	$1.3B+81.1%	$710.0M+19.9%	$592.0M+12.3%	$527.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$269.0M+2.3%	$263.0M+26.4%	$208.0M+27.6%	$163.0M-11.9%	$185.0M-11.9%	$210.0M
Income Tax	$109.0M+194.6%	$37.0M+156.1%	-$66.0M-140.5%	$163.0M+139.7%	$68.0M+270.0%	-$40.0M
Net Income	-$386.0M-659.4%	$69.0M+127.3%	-$253.0M-143.8%	$578.0M-4.9%	$608.0M+177.6%	$219.0M
EPS (Diluted)	$-2.57-658.7%	$0.46+127.1%	$-1.70-146.6%	$3.65+1.4%	$3.60+172.7%	$1.32

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.3B-11.1%	$1.5B-7.4%	$1.6B+18.1%	$1.4B+0.7%	$1.4B-9.9%	$1.5B-3.0%	$1.6B+14.1%	$1.4B
Cost of Revenue	$1.2B-7.0%	$1.3B-5.6%	$1.3B+18.1%	$1.1B+3.5%	$1.1B-10.5%	$1.2B-1.9%	$1.2B+15.6%	$1.1B
Gross Profit	$155.0M-33.5%	$233.0M-16.2%	$278.0M+17.8%	$236.0M-10.9%	$265.0M-7.3%	$286.0M-7.1%	$308.0M+8.5%	$284.0M
R&D Expenses	N/A	$26.0M-7.1%	$28.0M+3.7%	$27.0M	N/A	$29.0M+11.5%	$26.0M-7.1%	$28.0M
SG&A Expenses	N/A	$122.0M-71.2%	$424.0M+244.7%	$123.0M	N/A	$137.0M-11.0%	$154.0M+12.4%	$137.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$68.0M+1.5%	$67.0M+1.5%	$66.0M	N/A	$68.0M+3.0%	$66.0M+4.8%	$63.0M
Income Tax	N/A	-$8.0M-106.1%	$131.0M+2520.0%	$5.0M-58.3%	$12.0M	$0-100.0%	$9.0M-43.8%	$16.0M
Net Income	-$47.0M-202.2%	$46.0M+112.1%	-$380.0M-7500.0%	-$5.0M+54.5%	-$11.0M+65.6%	-$32.0M-153.3%	$60.0M+11.1%	$54.0M
EPS (Diluted)	$-0.31-200.0%	$0.31+112.3%	$-2.53-8333.3%	$-0.03+62.5%	$-0.08+63.6%	$-0.22-156.4%	$0.39+8.3%	$0.36

CC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.4B-1.7%	$7.5B-8.9%	$8.2B+7.9%	$7.6B+1.2%	$7.5B+6.6%	$7.1B
Current Assets	$3.0B-0.5%	$3.0B-21.5%	$3.8B+19.6%	$3.2B-3.9%	$3.3B+27.0%	$2.6B
Cash & Equivalents	$670.0M-6.0%	$713.0M-40.7%	$1.2B+9.2%	$1.1B-24.1%	$1.5B+31.3%	$1.1B
Inventory	$1.6B+7.2%	$1.5B+8.5%	$1.3B-3.9%	$1.4B+27.8%	$1.1B+17.0%	$939.0M
Accounts Receivable	$562.0M-9.2%	$619.0M+21.6%	$509.0M0.0%	$509.0M-21.0%	$644.0M+43.4%	$449.0M
Goodwill	$46.0M0.0%	$46.0M-54.9%	$102.0M0.0%	$102.0M0.0%	$102.0M-33.3%	$153.0M
Total Liabilities	$7.1B+2.8%	$6.9B-7.7%	$7.5B+15.1%	$6.5B+1.0%	$6.5B+3.2%	$6.3B
Current Liabilities	$1.7B-7.4%	$1.8B-26.8%	$2.5B+31.5%	$1.9B+1.8%	$1.9B+28.8%	$1.4B
Long-Term Debt	$4.1B+1.0%	$4.1B+1.8%	$4.0B+11.1%	$3.6B-3.6%	$3.7B-7.0%	$4.0B
Total Equity	$250.0M-56.2%	$571.0M-20.8%	$721.0M-34.9%	$1.1B+2.4%	$1.1B+33.0%	$813.0M
Retained Earnings	$1.2B-27.6%	$1.7B-5.4%	$1.8B-17.9%	$2.2B+24.3%	$1.7B+34.0%	$1.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$7.4B-2.2%	$7.5B+1.1%	$7.5B+1.2%	$7.4B-1.8%	$7.5B+0.7%	$7.5B+2.9%	$7.2B-9.2%	$8.0B
Current Assets	$3.0B-6.4%	$3.2B+3.5%	$3.1B+5.7%	$2.9B-2.8%	$3.0B-1.9%	$3.1B+4.7%	$2.9B-18.6%	$3.6B
Cash & Equivalents	$670.0M+9.3%	$613.0M+22.1%	$502.0M+8.2%	$464.0M-34.9%	$713.0M+19.6%	$596.0M-1.3%	$604.0M-19.0%	$746.0M
Inventory	$1.6B+1.4%	$1.5B-0.7%	$1.6B+0.5%	$1.6B+5.9%	$1.5B+2.0%	$1.4B+5.5%	$1.4B-1.7%	$1.4B
Accounts Receivable	$562.0M-31.2%	$817.0M+0.5%	$813.0M+15.5%	$704.0M+13.7%	$619.0M-25.0%	$825.0M+4.7%	$788.0M+13.9%	$692.0M
Goodwill	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M0.0%	$46.0M-54.9%	$102.0M0.0%	$102.0M
Total Liabilities	$7.1B-1.9%	$7.3B+0.5%	$7.2B+6.2%	$6.8B-1.8%	$6.9B+1.8%	$6.8B+4.3%	$6.5B-9.7%	$7.2B
Current Liabilities	$1.7B-9.9%	$1.9B+2.4%	$1.8B+9.5%	$1.7B-8.4%	$1.8B+1.9%	$1.8B+14.5%	$1.6B-30.1%	$2.2B
Long-Term Debt	$4.1B-0.1%	$4.1B-0.1%	$4.1B+1.0%	$4.1B+0.2%	$4.1B+1.8%	$4.0B+0.9%	$4.0B-0.4%	$4.0B
Total Equity	$250.0M-8.8%	$274.0M+20.2%	$228.0M-59.7%	$566.0M-0.9%	$571.0M-11.2%	$643.0M-9.9%	$714.0M-5.2%	$753.0M
Retained Earnings	$1.2B-4.8%	$1.3B+2.6%	$1.2B-23.9%	$1.6B-2.6%	$1.7B-3.7%	$1.7B-3.8%	$1.8B+1.2%	$1.8B

CC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$264.0M+141.7%	-$633.0M-213.8%	$556.0M-26.4%	$755.0M-7.2%	$814.0M+0.9%	$807.0M
Capital Expenditures	$213.0M-40.8%	$360.0M-2.7%	$370.0M+20.5%	$307.0M+10.8%	$277.0M+3.7%	$267.0M
Free Cash Flow	$51.0M+105.1%	-$993.0M-633.9%	$186.0M-58.5%	$448.0M-16.6%	$537.0M-0.6%	$540.0M
Investing Cash Flow	-$206.0M+41.6%	-$353.0M-54.1%	-$229.0M+19.4%	-$284.0M-229.1%	$220.0M+194.0%	-$234.0M
Financing Cash Flow	-$126.0M-250.0%	-$36.0M-120.9%	$172.0M+125.1%	-$686.0M-23.8%	-$554.0M-23.4%	-$449.0M
Dividends Paid	$78.0M-47.3%	$148.0M-0.7%	$149.0M-3.2%	$154.0M-6.1%	$164.0M0.0%	$164.0M
Share Buybacks	N/A	N/A	$69.0M-86.1%	$495.0M+186.1%	$173.0M	$0

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$137.0M-6.2%	$146.0M+57.0%	$93.0M+183.0%	-$112.0M-181.2%	$138.0M-0.7%	$139.0M+122.4%	-$620.0M-113.8%	-$290.0M
Capital Expenditures	$45.0M+9.8%	$41.0M-4.7%	$43.0M-48.8%	$84.0M-22.9%	$109.0M+43.4%	$76.0M+4.1%	$73.0M-28.4%	$102.0M
Free Cash Flow	$92.0M-12.4%	$105.0M+110.0%	$50.0M+125.5%	-$196.0M-775.9%	$29.0M-54.0%	$63.0M+109.1%	-$693.0M-76.8%	-$392.0M
Investing Cash Flow	-$43.0M-22.9%	-$35.0M+16.7%	-$42.0M+51.2%	-$86.0M+19.6%	-$107.0M-42.7%	-$75.0M-7.1%	-$70.0M+30.7%	-$101.0M
Financing Cash Flow	-$37.0M-640.0%	-$5.0M+81.5%	-$27.0M+52.6%	-$57.0M-167.1%	$85.0M+414.8%	-$27.0M+32.5%	-$40.0M+25.9%	-$54.0M
Dividends Paid	$15.0M+15.4%	$13.0M0.0%	$13.0M-64.9%	$37.0M+2.8%	$36.0M-5.3%	$38.0M+2.7%	$37.0M0.0%	$37.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	15.5%-4.2pp	19.8%-1.7pp	21.4%-2.2pp	23.7%+1.9pp	21.8%+0.3pp	21.5%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-6.7%-7.8pp	1.2%+5.3pp	-4.2%-12.6pp	8.5%-1.1pp	9.6%+5.2pp	4.4%
Return on Equity	-154.4%-166.5pp	12.1%+47.2pp	-35.1%-87.3pp	52.2%-4.0pp	56.2%+29.3pp	26.9%
Return on Assets	-5.2%-6.2pp	0.9%+4.0pp	-3.1%-10.6pp	7.6%-0.5pp	8.1%+5.0pp	3.1%
Current Ratio	1.78+0.1	1.66+0.1	1.55-0.2	1.70-0.1	1.80-0.0	1.83
Debt-to-Equity	16.40+9.3	7.11+1.6	5.53+2.3	3.24-0.2	3.44-1.5	4.93
FCF Margin	0.9%+18.1pp	-17.2%-20.2pp	3.1%-3.5pp	6.6%-1.9pp	8.5%-2.4pp	10.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	11.7%-3.9pp	15.6%-1.6pp	17.2%-0.0pp	17.3%-2.3pp	19.5%+0.5pp	19.0%-0.8pp	19.8%-1.0pp	20.8%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-3.5%-6.6pp	3.1%+26.6pp	-23.5%-23.2pp	-0.4%+0.4pp	-0.8%+1.3pp	-2.1%-6.0pp	3.9%-0.1pp	4.0%
Return on Equity	-18.8%-35.6pp	16.8%+183.5pp	-166.7%-165.8pp	-0.9%+1.1pp	-1.9%+3.0pp	-5.0%-13.4pp	8.4%+1.2pp	7.2%
Return on Assets	-0.6%-1.3pp	0.6%+5.7pp	-5.1%-5.0pp	-0.1%+0.1pp	-0.1%+0.3pp	-0.4%-1.3pp	0.8%+0.2pp	0.7%
Current Ratio	1.78+0.1	1.71+0.0	1.70-0.1	1.76+0.1	1.66-0.1	1.72-0.2	1.88+0.3	1.62
Debt-to-Equity	16.40+1.4	14.98-3.0	18.02+10.8	7.19+0.1	7.11+0.9	6.20+0.7	5.54+0.3	5.27
FCF Margin	6.9%-0.1pp	7.0%+3.9pp	3.1%+17.4pp	-14.3%-16.5pp	2.1%-2.0pp	4.2%+48.8pp	-44.6%-15.8pp	-28.8%

Similar Companies

$2.5B

$2.1B

$2.5B

$1.8B

$2.2B

Frequently Asked Questions

What is Chemours Co's annual revenue?

Chemours Co (CC) reported $5.8B in total revenue for fiscal year 2025. This represents a 0.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Chemours Co's revenue growing?

Chemours Co (CC) revenue grew by 0.4% year-over-year, from $5.8B to $5.8B in fiscal year 2025.

Is Chemours Co profitable?

No, Chemours Co (CC) reported a net income of -$386.0M in fiscal year 2025, with a net profit margin of -6.7%.

How much debt does Chemours Co have?

As of fiscal year 2025, Chemours Co (CC) had $670.0M in cash and equivalents against $4.1B in long-term debt.

What is Chemours Co's gross margin?

Chemours Co (CC) had a gross margin of 15.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Chemours Co's net profit margin?

Chemours Co (CC) had a net profit margin of -6.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Chemours Co pay dividends?

Yes, Chemours Co (CC) paid $0.51 per share in dividends during fiscal year 2025.

What is Chemours Co's return on equity (ROE)?

Chemours Co (CC) has a return on equity of -154.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Chemours Co's free cash flow?

Chemours Co (CC) generated $51.0M in free cash flow during fiscal year 2025. This represents a 105.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Chemours Co's operating cash flow?

Chemours Co (CC) generated $264.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Chemours Co's total assets?

Chemours Co (CC) had $7.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Chemours Co's capital expenditures?

Chemours Co (CC) invested $213.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Chemours Co spend on research and development?

Chemours Co (CC) invested $108.0M in research and development during fiscal year 2025.

How many shares does Chemours Co have outstanding?

Chemours Co (CC) had 150M shares outstanding as of fiscal year 2025.

What is Chemours Co's current ratio?

Chemours Co (CC) had a current ratio of 1.78 as of fiscal year 2025, which is generally considered healthy.

What is Chemours Co's debt-to-equity ratio?

Chemours Co (CC) had a debt-to-equity ratio of 16.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Chemours Co's return on assets (ROA)?

Chemours Co (CC) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Chemours Co's Piotroski F-Score?

Chemours Co (CC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Chemours Co's earnings high quality?

Chemours Co (CC) has an earnings quality ratio of -0.68x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Chemours Co?

Chemours Co (CC) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.